Sangamo Therapeutics Inc (NASDAQ:SGMO)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $11.34, but opened at $11.37. Sangamo Therapeutics shares last traded at $11.53, with a volume of 77,757 shares trading hands.
Several research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 16th. BidaskClub raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 28th. HC Wainwright initiated coverage on shares of Sangamo Therapeutics in a report on Monday, August 26th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Wedbush reissued a “hold” rating and set a $11.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $13.50.
The company’s 50 day moving average price is $9.48 and its 200-day moving average price is $10.23. The stock has a market cap of $1.30 billion, a P/E ratio of -16.54 and a beta of 2.84. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.77 and a current ratio of 4.77.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative net margin of 159.12% and a negative return on equity of 30.33%. The business had revenue of $21.96 million for the quarter, compared to analysts’ expectations of $12.16 million. During the same period in the previous year, the company earned ($0.13) earnings per share. The firm’s revenue for the quarter was down 6.8% compared to the same quarter last year. On average, analysts forecast that Sangamo Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of the business. Metropolitan Life Insurance Co NY grew its holdings in shares of Sangamo Therapeutics by 20.7% in the third quarter. Metropolitan Life Insurance Co NY now owns 38,292 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 6,557 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in Sangamo Therapeutics by 184.1% during the third quarter. Squarepoint Ops LLC now owns 174,740 shares of the biopharmaceutical company’s stock worth $1,581,000 after acquiring an additional 113,232 shares during the period. Granahan Investment Management Inc. MA boosted its position in Sangamo Therapeutics by 7.8% in the third quarter. Granahan Investment Management Inc. MA now owns 101,619 shares of the biopharmaceutical company’s stock worth $920,000 after purchasing an additional 7,370 shares during the last quarter. California State Teachers Retirement System boosted its position in Sangamo Therapeutics by 1.6% in the third quarter. California State Teachers Retirement System now owns 179,615 shares of the biopharmaceutical company’s stock worth $1,626,000 after purchasing an additional 2,752 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Sangamo Therapeutics in the 3rd quarter valued at $514,000. 70.78% of the stock is currently owned by hedge funds and other institutional investors.
Sangamo Therapeutics Company Profile (NASDAQ:SGMO)
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Read More: What is the return on assets (ROA) ratio?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.